Online inquiry

IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4284MR)

This product GTTS-WQ4284MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SNCA gene. The antibody can be applied in Parkinson's disease (PD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000345.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6622
UniProt ID P37840
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4284MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15299MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ15767MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ10215MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LFB-R593
GTTS-WQ8241MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX-06
GTTS-WQ12448MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12904MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ7890MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ14439MR IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO4858696-000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW